When an eminent cardiologist like Dr. Sunil Chandy—former Director...

Catalyzed by the pandemic, the pharma industry quickly progressed from being digitally agnostic to a state of preparedness. The shift required the industry to experiment with technology in its customer-facing plans, which resulted in many cases the creation of random acts of digital, often without a cohesive overarching strategy. Can pharma do better? The answer lies in understanding the utility of their digital assets while building a mindset to transform, and ensuring that teams within the organization do not work at cross-purposes.

IPM Momentum, Innovation Waves & the AQI-Driven Respiratory Surge...

The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered. The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model. Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison. ‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product. Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it. A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it. The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).

The Paradox of Protection In the time it takes to...

Opening Frame: The "Silent" Pandemic Meets Strategic Grit In the...

A Tale of Two Truths: Severance, Up in the...

Sachhin Misshra has been elevated to the role of...

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

How the 2026 U.S. tariff action on branded drugs...

Opening Frame: The "Silent" Pandemic Meets Strategic Grit In the...

A Tale of Two Truths: Severance, Up in the...

Sachhin Misshra has been elevated to the role of...

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

How the 2026 U.S. tariff action on branded drugs...

Opening Frame: The "Silent" Pandemic Meets Strategic Grit In the...

A Tale of Two Truths: Severance, Up in the...

Sachhin Misshra has been elevated to the role of...

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

How the 2026 U.S. tariff action on branded drugs...

Opening Frame: The "Silent" Pandemic Meets Strategic Grit In the...

A Tale of Two Truths: Severance, Up in the...

Sachhin Misshra has been elevated to the role of...

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

How the 2026 U.S. tariff action on branded drugs...